Shandong Xinhua Pharmaceutical Company Limited (XIN) - Net Assets

Latest as of March 2026: €5.60 Billion EUR ≈ $6.54 Billion USD

Based on the latest financial reports, Shandong Xinhua Pharmaceutical Company Limited (XIN) has net assets worth €5.60 Billion EUR (≈ $6.54 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.07 Billion ≈ $10.60 Billion USD) and total liabilities (€3.47 Billion ≈ $4.06 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check XIN goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€5.60 Billion
% of Total Assets	61.7%
Annual Growth Rate	9.27%
5-Year Change	49.43%
10-Year Change	162.38%
Growth Volatility	6.16

Shandong Xinhua Pharmaceutical Company Limited - Net Assets Trend (2013–2025)

This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited's net assets have evolved over time, based on quarterly financial data. See XIN defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Shandong Xinhua Pharmaceutical Company Limited (2013–2025)

The table below shows the annual net assets of Shandong Xinhua Pharmaceutical Company Limited from 2013 to 2025. For live valuation and market cap data, see Shandong Xinhua Pharmaceutical Company L market cap and net worth.

Year	Net Assets	Change
2025-12-31	€5.46 Billion ≈ $6.38 Billion	+4.57%
2024-12-31	€5.22 Billion ≈ $6.10 Billion	+9.25%
2023-12-31	€4.78 Billion ≈ $5.58 Billion	+9.79%
2022-12-31	€4.35 Billion ≈ $5.09 Billion	+19.14%
2021-12-31	€3.65 Billion ≈ $4.27 Billion	+7.66%
2020-12-31	€3.39 Billion ≈ $3.96 Billion	+9.03%
2019-12-31	€3.11 Billion ≈ $3.64 Billion	+11.23%
2018-12-31	€2.80 Billion ≈ $3.27 Billion	+8.42%
2017-12-31	€2.58 Billion ≈ $3.02 Billion	+24.05%
2016-12-31	€2.08 Billion ≈ $2.43 Billion	+4.80%
2015-12-31	€1.98 Billion ≈ $2.32 Billion	+3.78%
2014-12-31	€1.91 Billion ≈ $2.24 Billion	+1.51%
2013-12-31	€1.88 Billion ≈ $2.20 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to Shandong Xinhua Pharmaceutical Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 307.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	€2.65 Billion	50.81%
Other Components	€2.56 Billion	49.19%
Total Equity	€5.21 Billion	100.00%

Shandong Xinhua Pharmaceutical Company Limited Competitors by Market Cap

The table below lists competitors of Shandong Xinhua Pharmaceutical Company Limited ranked by their market capitalization.

Company	Market Cap
Benchmark Holdings Plc LSE:BMK	$135.69 Million
PT Net Visi Media Tbk JK:NETV	$135.72 Million
IKIO Lighting Limited NSE:IKIO	$135.78 Million
Enablence Technologies Inc V:ENA	$135.80 Million
Pyridam Farma Tbk JK:PYFA	$135.64 Million
RCM Technologies Inc NASDAQ:RCMT	$135.61 Million
Lindsell Train Investment Trust Plc LSE:LTI	$135.60 Million
Dwi Guna Laksana Tbk PT JK:DWGL	$135.54 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shandong Xinhua Pharmaceutical Company Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 4,991,588,525 to 5,208,753,245, a change of 217,164,720 (4.4%).
Net income of 289,888,855 contributed positively to equity growth.
Dividend payments of 209,780,052 reduced retained earnings.
Other factors increased equity by 137,055,917.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	€289.89 Million	+5.57%
Dividends Paid	€209.78 Million	-4.03%
Other Changes	€137.06 Million	+2.63%
Total Change	€-	4.35%

Book Value vs Market Value Analysis

This analysis compares Shandong Xinhua Pharmaceutical Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.08x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	€3.99	€0.60	x
2018-12-31	€4.32	€0.60	x
2019-12-31	€4.77	€0.60	x
2020-12-31	€5.18	€0.60	x
2021-12-31	€5.53	€0.60	x
2022-12-31	€6.16	€0.60	x
2023-12-31	€6.75	€0.60	x
2024-12-31	€7.31	€0.60	x
2025-12-31	€7.55	€0.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shandong Xinhua Pharmaceutical Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 5.57%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.31%
• Asset Turnover: 0.95x
• Equity Multiplier: 1.76x
Recent ROE (5.57%) is below the historical average (7.64%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	2.17%	1.15%	0.85x	2.22x	€-141.15 Million
2014	2.79%	1.41%	0.85x	2.33x	€-131.34 Million
2015	4.41%	2.31%	0.80x	2.38x	€-105.36 Million
2016	6.15%	3.05%	0.85x	2.38x	€-76.57 Million
2017	8.45%	4.64%	0.86x	2.13x	€-38.41 Million
2018	9.33%	4.82%	0.88x	2.20x	€-17.89 Million
2019	10.10%	5.35%	0.87x	2.17x	€3.06 Million
2020	10.08%	5.41%	0.85x	2.20x	€2.48 Million
2021	10.05%	5.31%	0.89x	2.11x	€1.75 Million
2022	9.96%	5.48%	0.91x	2.00x	€-1.45 Million
2023	10.90%	6.13%	0.98x	1.82x	€41.20 Million
2024	9.42%	5.55%	0.94x	1.81x	€-29.14 Million
2025	5.57%	3.31%	0.95x	1.76x	€-230.99 Million

Industry Comparison

This section compares Shandong Xinhua Pharmaceutical Company Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $6,888,924,775
Average return on equity (ROE) among peers: -44.00%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shandong Xinhua Pharmaceutical Company Limited (XIN)	€5.60 Billion	2.17%	0.62x	$135.65 Million
SHANG.FOS.PHARM.GR.H YC 1 (08HH)	$61.84 Billion	5.45%	0.94x	$1.13 Billion
PEPTONIC MEDICAL (28L)	$47.09 Million	-78.27%	0.82x	$4.14 Million
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ)	$6.55 Billion	13.15%	0.55x	$692.11 Million
WEST ISLAND BRANDS INC. (39N0)	$3.27 Million	-157.21%	0.88x	$1.34 Million
AYURCANN HOLDINGS CORP. (3ZQ0)	$2.69 Million	-197.11%	3.73x	$97.35K
CERENO SCIENTIFIC AB B (4A1)	$216.42 Million	-22.23%	0.32x	$157.72 Million
MAPLE LEAF GREEN WORLD (4HV0)	$-9.91 Million	0.00%	0.00x	$504.30K
LORDS CO. WORLDW. HOLD. (4XM)	$-1.01 Million	0.00%	0.00x	$134.78K
RED LIGHT HOLLAND CORP. (4YX)	$17.35 Million	-23.30%	0.22x	$13.93 Million
EQL PHARMA AB (7JK)	$221.03 Million	19.51%	2.66x	$78.37 Million

About Shandong Xinhua Pharmaceutical Company Limited

F:XIN Germany Drug Manufacturers - Specialty & Generic

Market Cap

$135.65 Million

€116.03 Million EUR

Market Cap Rank

#18118 Global

#1687 in Germany

Share Price

€0.60

Change (1 day)

-0.83%

52-Week Range

€0.59 - €0.97

All Time High

€0.97